Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2010 Aug;12(4):252-7.
doi: 10.1007/s11906-010-0126-2.

Mineralocorticoid receptor antagonists and the metabolic syndrome

Amir Tirosh  1 , Rajesh Garg, Gail K Adler
Affiliations
Review

Mineralocorticoid receptor antagonists and the metabolic syndrome

Amir Tirosh et al. Curr Hypertens Rep. 2010 Aug.

Abstract

Key components of the metabolic syndrome (MetS), ie, obesity and insulin resistance, are associated with increased aldosterone production and mineralocorticoid receptor (MR) activation. Both MetS and hyperaldosteronism are proinflammatory and pro-oxidative states associated with cardiovascular disease. This review discusses emerging data that MR activation may contribute to abnormalities seen in MetS. In view of these data, MR antagonists may be beneficial in MetS, not only by controlling hypertension but also by reversing inflammation, oxidative stress, and defective insulin signaling at the cellular-molecular level. Clinical trials have demonstrated benefits of MR antagonists in heart failure, hypertension, and diabetic nephropathy, but additional trials are needed to demonstrate the clinical significance of MR blockade in MetS.

PubMed Disclaimer

Conflict of interest statement

Disclosure No potential conflicts of interest relevant to this article were reported.

Figures

Fig. 1
Fig. 1
Aldosterone, obesity, and the metabolic syndrome share common features that underlie the pathophysiology of cardiovascular disease
See this image and copyright information in PMC

References

    1. McNeill AM, Rosamond WD, Girman CJ, et al. The metabolic syndrome and 11-year risk of incident cardiovascular disease in the Atherosclerosis Risk in Communities study. Diabetes Care. 2005;28:385–390. - PubMed
    1. Chen J, Muntner P, Hamm LL, et al. The metabolic syndrome and chronic kidney disease in U.S. adults. Ann Intern Med. 2004;140:167–174. - PubMed
    1. Wilson PW, D’Agostino RB, Parise H, et al. Metabolic syndrome as a precursor of cardiovascular disease and type 2 diabetes mellitus. Circulation. 2005;112:3066–3072. - PubMed
    1. Wang J, Sarnola K, Ruotsalainen S, et al. The metabolic syndrome predicts incident congestive heart failure: a 20-year follow-up study of elderly Finns. Atherosclerosis. 2010;210:237–242. - PubMed
    1. Wang J, Ruotsalainen S, Moilanen L, et al. The metabolic syndrome predicts cardiovascular mortality: a 13-year follow-up study in elderly non-diabetic Finns. Eur Heart J. 2007;28:857–864. - PubMed

Publication types

MeSH terms